기본 통계
| LEI | 529900242I3SV9AGM753 |
| CIK | 1159036 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Halozyme Therapeutics, Inc.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME T |
|
| May 11, 2026 |
Exhibit 99.1 HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026 Total Revenue Increased 42% YOY to $377 million Royalty Revenue Increased 43% YOY to $241 million Reiterating 2026 Financial Guidance Ranges: Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22 |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of in |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| April 30, 2026 |
Halozyme Appoints Darren Snellgrove as Chief Financial Officer Exhibit 99.1 Halozyme Appoints Darren Snellgrove as Chief Financial Officer SAN DIEGO, April 30, 2026 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today announced the appointment of Darren Snellgrove as Chief Financial Officer (CFO), effective June 8, 2026. Mr. Snellgrove will be responsible for leading Halozyme’s financial operations and strategy, including capital a |
|
| April 24, 2026 |
BYLAWS OF HALOZYME THERAPEUTICS, INC. ARTICLE I STOCKHOLDERS Exhibit 3.1 BYLAWS OF HALOZYME THERAPEUTICS, INC. ARTICLE I STOCKHOLDERS 1.1 Place of Meetings. All meetings of stockholders shall be held at such place (if any) within or without the State of Delaware as may be designated from time to time by the Board of Directors (the “Board”). 1.2 Annual Meeting. The annual meeting of stockholders for the election of directors and for the transaction of such o |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 22, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| March 23, 2026 |
2026 Annual ReportIn addition to these new partnerships, we also executed two new development agreements for our auto-injector technology and entered into a commercial and licensing supply agreement with Viatris for our validated small-volume auto-injector. |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 12, 2026 |
Halozyme Appoints David Ramsay as Interim Chief Financial Officer Exhibit 99.1 Halozyme Appoints David Ramsay as Interim Chief Financial Officer SAN DIEGO, March 12, 2026 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a p |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| February 17, 2026 |
AMENDMENT NO. 3 TO CREDIT AGREEMENT Exhibit 10.7 Execution Version AMENDMENT NO. 3 TO CREDIT AGREEMENT AMENDMENT NO. 3 TO CREDIT AGREEMENT, dated as of November 5, 2025 (this “Amendment”), by and among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), the Guarantors (as defined in the Credit Agreement referred to below), each Extending Revolving Credit Lender (as defined below), each Additional Revolving Credit L |
|
| February 17, 2026 |
Exhibit 99.1 HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi’s Hypercon™ Technology and Surf Bio’s Hyperconcentration Technology Reiterating 2026 Financial Gui |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 17, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| February 17, 2026 |
EXHIBIT 21.1 SUBSIDIARIES OF HALOZYME THERAPEUTICS, INC. Name of Subsidiary State or Jurisdiction of Incorporation or Organization Percent Owned Halozyme, Inc. California 100% Antares Pharma, Inc. Delaware 100% Antares Pharma IPL AG Switzerland 100% Antares Pharma GmbH Switzerland 100% Halozyme Hypercon, Inc. Delaware 100% Elektrofi Security Corp. Massachusetts 100% Halozyme Surf Bio, Inc. Delawar |
|
| February 17, 2026 |
HALOZYME THERAPEUTICS, INC. INSIDER TRADING POLICY Exhibit 19.1 HALOZYME THERAPEUTICS, INC. INSIDER TRADING POLICY I. Trading in Company Securities While in Possession of Material Nonpublic Information is Prohibited The purchase or sale of Halozyme securities by any person who possesses material nonpublic information about Halozyme is a violation of federal and state securities laws. Furthermore, it is important that the appearance, as well as the |
|
| February 17, 2026 |
TRANSITION AND RELEASE AGREEMENT Exhibit 10.36 TRANSITION AND RELEASE AGREEMENT THIS TRANSITION AND RELEASE AGREEMENT (the “Agreement”) is entered into by and between Nicole LaBrosse (“Ms. LaBrosse”) and Halozyme Therapeutics, Inc. (the “Company”) (collectively, the “Parties”). WHEREAS, Ms. LaBrosse is currently employed by the Company as Chief Financial Officer (“CFO”); WHEREAS, the Company has advised Ms. LaBrosse that it plans |
|
| February 17, 2026 |
Exhibit 10.37 Halozyme Therapeutics, Inc. Performance Stock Units Agreement – Absolute Stock Price Grant under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Vesting. All of the Performance Units are nonvested |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAP |
|
| January 28, 2026 |
Exhibit 99.1 Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1 - Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30% |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2026 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| December 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 4, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| December 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 4, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| November 18, 2025 |
As filed with the Securities and Exchange Commission on November 18, 2025 As filed with the Securities and Exchange Commission on November 18, 2025 Registration No. |
|
| November 18, 2025 |
ELEKTROFI, INC. 2015 EQUITY INCENTIVE PLAN TABLE OF CONTENTS 2. Definitions.............................................................................................................. 1 3. Term of the Plan..................................................................................................... 3 4. Stock Subject to the Plan............................................................. |
|
| November 18, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) Halozyme Therapeutics, Inc. |
|
| November 12, 2025 |
Synthetic Instrument Adjusted Issue Price19 EX-10.1 Exhibit 10.1 Form To: Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego, CA 92130 From: [ ⚫ ] Re: [Base]1[Additional]2 Capped Call Transaction Ref. No: [ ⚫ ]3 Date: [ ⚫ ] Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the |
|
| November 12, 2025 |
EX-4.3 EXHIBIT 4.3 HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of November 12, 2025 0.875% Convertible Senior Notes due 2032 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 12 Section 1.03. Rules of Construction 13 Article 2. The Notes 14 Section 2 |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 12, 2025 |
EX-4.1 EXHIBIT 4.1 HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of November 12, 2025 0% Convertible Senior Notes due 2031 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 12 Section 1.03. Rules of Construction 13 Article 2. The Notes 13 Section 2. |
|
| November 7, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 SAN DIEGO, CA (November 6, 2025) — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), today announced the pricing of $650 million aggregate principal amount of 0% conver |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 5, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 SAN DIEGO, CA (November 5, 2025) — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), today announced that it intends to offer, subject to market conditions and other factors, $65 |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZY |
|
| November 3, 2025 |
Exhibit 99.1 HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS Royalty Revenue Increased 52% YOY to Record $236 million and Total Revenue Increased 22% YOY to Record $354 million Net Income Increased 28% YOY to $175 million; Adjusted EBITDA Increased 35% YOY to $248 million; GAAP Diluted EPS Increased 36% YOY to $1.43; Non-GAAP Diluted EP |
|
| October 14, 2025 |
halozymestatementoncmsfi 1 CMS Final IPAY 2028 Guidance for the IRA Medicare Part B Price Negotiations Halozyme Position Statement 2 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance, including the Company’s expectations of the impact to future royalty revenue as a result of implementation of IPAY price negotiations for Part B drugs, the portion of future projected ENHANZE® global sales derived from U. |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 14, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| October 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| October 3, 2025 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG ELEKTROFI, INC., HALOZYME THERAPEUTICS, INC., ERRAID MERGER SUB INC. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC SEPTEMBER 30, 2025 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL TABLE OF CONTENTS Pa |
|
| October 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| October 1, 2025 |
EX-99.1 Exhibit 99.1 Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP ex |
|
| October 1, 2025 |
144 0001528185 XXXXXXXX LIVE 0001159036 Halozyme Therapeutics, Inc. 001-32335 12390 El Camino Real San Diego CA 92130 858-794-8889 Helen Torley President, CEO, Director Common Stock J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017 136569 10015970 116966000 10/01/2025 NASDAQ Common Stock 10/01/2025 Stock Option Exercise Issuer N 136569 10/01/2025 Cash N Helen Torley C/o H |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| September 10, 2025 |
144 0001910662 XXXXXXXX LIVE 0001159036 HALOZYME THERAPEUTICS INC 001-32335 12390 El Camino Real San Diego CA 92130 858-794-8889 NICOLE LABROSSE Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 22227 1690807. |
|
| September 2, 2025 |
144 0001662521 XXXXXXXX LIVE 0001159036 HALOZYME THERAPEUTICS, INC. 001-32335 12390 El Camino Real San Diego CA 92130 858-794-8889 BERNADETTE CONNAUGHTON Director Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 8829 645841.35 116966000 09/02/2025 NASDAQ Common 04/30/2021 Restricted Stock Units Issuer N 8829 04/30/2021 N/A Y 09/02/202 |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME TH |
|
| August 5, 2025 |
Exhibit 99.1 HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to $1.541 |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME T |
|
| May 6, 2025 |
Performance Stock Units Agreement (202 Exhibit 10.1 Halozyme Therapeutics, Inc. Performance Stock Units Agreement – Deal/Nominations under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Vesting. All of the Performance Units are nonvested and forfeit |
|
| May 6, 2025 |
Exhibit 99.1 HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Dil |
|
| May 6, 2025 |
TSR Performance Stock Units Agreement (2021 Stock Plan) Exhibit 10.2 Halozyme Therapeutics, Inc. Performance Stock Units Agreement – Relative TSR under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Vesting. All of the Performance Units are nonvested and forfeitable |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 17, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 18, 2025 |
2024 Annual Report58% year-over-year to $444 million and adjusted EBITDA increased 48% year-over-year to $632 million. |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 18, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAP |
|
| February 18, 2025 |
Exhibit 99.1 HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE of $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA and NON-GAAP DILUTED EPS Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 milli |
|
| February 18, 2025 |
alozyme Therapeutics, Inc. Insider Trading Policy Revised: December 2, 2024 HALOZYME THERAPEUTICS, INC. INSIDER TRADING POLICY I. Trading in Company Securities While in Possession of Material Nonpublic Information is Prohibited The purchase or sale of Halozyme securities by any person who possesses material nonpublic information about Halozyme is a violation of federal and state securities laws. Furthermore, it is important that the appearance, a |
|
| February 18, 2025 |
EXHIBIT 21.1 SUBSIDIARIES OF HALOZYME THERAPEUTICS, INC. Name of Subsidiary State or Jurisdiction of Incorporation or Organization Percent Owned Halozyme, Inc. California 100% Antares Pharma, Inc. Delaware 100% Antares Pharma IPL AG Switzerland 100% Antares Pharma AG Switzerland 100% |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 11, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| January 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| January 8, 2025 |
Exhibit 99.1 Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32 |
|
| November 12, 2024 |
SC 13G/A 1 d883368dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Halozyme Therapeutics Inc. (Name of Issuer) Common Stock (Ti |
|
| November 12, 2024 |
EX-99.1 2 d883368dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 11/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTI |
|
| October 31, 2024 |
Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271 Raised 2024 Financial |
|
| October 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2024 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZY |
|
| October 17, 2024 |
HALO / Halozyme Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G 1 HalozymeTheraInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HALOZYME THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 40637H109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME TH |
|
| August 6, 2024 |
Form of Restricted Stock Units Agreement (2021 Plan Sell-to-Cover updated June 2024) EXHIBIT 10.1 Halozyme Therapeutics, Inc. Restricted Stock Units Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Vesting. All of the Restricted Stock Units are nonvested and forfeitable as of the |
|
| August 6, 2024 |
Exhibit 99.1 HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.911 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus® SC in Europe and the UK and VYVGART® Hytrulo for CIDP in the U.S. Maintain Recently I |
|
| May 7, 2024 |
Exhibit 99.1 HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of $915 - $985 million, Representing YOY Growth of 10% |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2024 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME T |
|
| April 26, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2024 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| April 26, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HALOZYME THERAPEUTICS, INC. FIRST: The name of the corporation is: Halozyme Therapeutics, Inc. SECOND: The address of its registered office in the State of Delaware is The Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle. The name of the registered agent at that address is The Corporation Trust |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 15, 2024 |
2023 Annual ReportWe are proud of the many milestones and accomplishments that we achieved as an organization and with our partners throughout the year. |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 20, 2024 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| February 20, 2024 |
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3. |
|
| February 20, 2024 |
Halozyme Therapeutics, Inc. Incentive Compensation Recoupment Policy Exhibit 97 Incentive Compensation Recoupment Policy As Amended and Restated by the Board of Directors on October 16, 2023 In the event Halozyme Therapeutics, Inc. |
|
| February 20, 2024 |
EXHIBIT 21.1 SUBSIDIARIES OF HALOZYME THERAPEUTICS, INC. Name of Subsidiary State or Jurisdiction of Incorporation or Organization Percent Owned Halozyme, Inc. California 100% Antares Pharma, Inc. Delaware 100% Antares Pharma IPL AG Switzerland 100% Antares Pharma AG Switzerland 100% |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAP |
|
| February 20, 2024 |
EXHIBIT 10.28 HALOZYME THERAPEUTICS, INC. SEVERANCE POLICY Under the Severance Policy of Halozyme Therapeutics, Inc. (the “Company”), the particular amount of cash severance for an employee terminated by the Company without “Cause” (as defined below) will generally be dictated by the employee’s position in the organization as well their completed years of service with the Company. The Severance Po |
|
| February 13, 2024 |
HALO / Halozyme Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01066-halozymetherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Halozyme Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 40637H109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 12, 2024 |
SC 13G/A 1 d754689dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Halozyme Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class |
|
| February 12, 2024 |
EX-99.1 2 d754689dex991.htm EX-99.1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree to the joint filing of the Schedule 13G to which this Agreement is attached. Dated: 2/12/2024 ARTISAN PARTNERS ASSET MANAGEMENT INC, for itself and as the general partner of ARTISAN PARTNERS HOLDINGS LP By: Gregory K. Ramirez * ARTISAN INVESTMENTS GP LLC, for itself and as the general partner of ARTIS |
|
| February 1, 2024 |
HALO / Halozyme Therapeutics, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Halozyme Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 23, 2024 |
HALO / Halozyme Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us40637h1095012324.txt us40637h1095012324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) HALOZYME THERAPEUTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 40637H109 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 17, 2024 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 6, 2023 |
Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.751 Maintained Revenue Guidance and Raised 2023 EBITDA Guidance to $430-$445 million and Non-GAAP EPS Guidance to $2.70-$2 |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZY |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 6, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| August 8, 2023 |
Letter Agreement Amending Exercise Period for Employee Option 12390 El Camino Real San Diego, California 92130 Main: (858) 794-8889 Fax: (858) 704-8311 [Date] [Employee Name] Dear [First Name], You hold one or more stock options granted by Halozyme Therapeutics, Inc. |
|
| August 8, 2023 |
Form of Restricted Stock Units Agreement (2021 Plan Sell-to-Cover updated May 2023) Halozyme Therapeutics, Inc. Restricted Stock Units Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Vesting. All of the Restricted Stock Units are nonvested and forfeitable as of the Grant Date. S |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME TH |
|
| August 8, 2023 |
Form of Stock Option Agreement (2021 Plan updated May 2023) HALOZYME THERAPEUTICS, INC. Employee Stock Option AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2021 STOCK PLAN 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Exercise of the Option. 2.1 Right to Exercise. Except as otherwise provided herein, the Option sh |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 8, 2023 |
Form of Restricted Stock Units Agreement for Officers (2021 Plan updated May 2023) Halozyme Therapeutics, Inc. Restricted Stock Units Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Vesting. All of the Restricted Stock Units are nonvested and forfeitable as of the Grant Date. S |
|
| August 8, 2023 |
Form of Director Stock Option Agreement (2021 Plan) HALOZYME THERAPEUTICS, INC. Director Stock Option AGREEMENT UNDER THE HALOZYME THERAPEUTICS, INC. 2021 STOCK PLAN 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Exercise of the Option. 2.1 Right to Exercise. Except as otherwise provided herein, the Option sh |
|
| August 8, 2023 |
Exhibit 99.1 HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.741 Royalty Revenue Increased 31% YOY to Record $111.7 million Raised 2023 Non-GAAP Diluted EPS Guidance to $2.65-$2.75 Updated Revenue Guidance to $825-$845 million, Representing 25-28% YOY Growth, and EBITDA Guidan |
|
| July 21, 2023 |
United States securities and exchange commission logo July 21, 2023 Nicole LaBrosse Senior Vice President and Chief Financial Officer Halozyme Therapeutics, Inc. |
|
| June 28, 2023 |
Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego, CA 92130 Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego, CA 92130 June 27, 2023 VIA EDGAR Ms. Mary Mast Ms. Angela Connell Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Halozyme Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 21, 2023 File No. 001-32335 Dear Ms. Mast an |
|
| June 14, 2023 |
United States securities and exchange commission logo June 14, 2023 Nicole LaBrosse Senior Vice President and Chief Financial Officer Halozyme Therapeutics, Inc. |
|
| June 9, 2023 |
HALO / Halozyme Therapeutics Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Halozyme Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 40637H109 Date of Event Which Requires Filing of this Statement: May 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME T |
|
| May 9, 2023 |
Amendment No. 2 to the Credit Agreement AMENDMENT NO. 2 TO THE CREDIT AGREEMENT AMENDMENT NO. 2 to the CREDIT AGREEMENT, dated as of March 1, 2023 (this “Amendment”), is made by and among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Borrower”) and BANK OF AMERICA, N.A., as administrative agent (in such capacity, the “Administrative Agent”). WHEREAS, reference is hereby made to the Credit Agreement, dated as of May 24, 2022 |
|
| May 9, 2023 |
Exhibit 99.1 HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.471 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating 2023 Revenue Guidance of $815-$845 million, Representing 23-28% YOY Growth; EBITDA of $415-$440 million, Representing >3 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 24, 2023 |
Annual Report 20222022 was a transformative year for Halozyme. We delivered record revenue from our ENHANZE ® business and extended our drug delivery leadership and expanded our commercial portfolio with the acquisition of Antares Pharma. We had many successes and learnings this year and together, as One Team, we demonstrated operational excellence throughout the organization for the benefit of pat |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 16, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| March 16, 2023 |
Exhibit 99.1 HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPRO® and SC through at least 2030 Reiterates 2023 Revenue Guidance of $815 million to $845 million and Royalty Revenue of $445 million to $455 million SAN DIEGO, March 15, 2023 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“H |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC |
|
| February 21, 2023 |
Exhibit 99.1 HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS Fourth Quarter Revenue Increased 78% YOY to $181 million; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.481 Full Year 2022 Revenue Increased 49% YOY to $660.1 million; GAAP Diluted Earnings per Share of $1.44 and Non-GAAP Diluted Earnings per Share of $2.211 Reco |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| February 21, 2023 |
EXHIBIT 21.1 SUBSIDIARIES OF HALOZYME THERAPEUTICS, INC. Name of Subsidiary State or Jurisdiction of Incorporation or Organization Percent Owned Halozyme, Inc. California 100% Antares Pharma, Inc Delaware 100% Antares Pharma IPL AG Switzerland 100% Antares Pharma AG Switzerland 100% |
|
| February 10, 2023 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 3)* Halozyme Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP |
|
| February 10, 2023 |
Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd. |
|
| February 10, 2023 |
HALO / Halozyme Therapeutics, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Halozyme Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 40637H109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 10, 2023 |
HALO / Halozyme Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us40637h1095021023.txt us40637h1095021023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) HALOZYME THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 40637H109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 9, 2023 |
HALO / Halozyme Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01032-halozymetherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Halozyme Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 40637H109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 3, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| January 26, 2023 |
HALO / Halozyme Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us40637h1095012623.txt us40637h1095012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) HALOZYME THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 40637H109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| January 20, 2023 |
HALO / Halozyme Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G 1 us40637h1095012023.txt us40637h1095012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) HALOZYME THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 40637H109 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2023 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| January 10, 2023 |
Halozyme Provides 2023 Financial Guidance and Outlook 2023 Total Revenue Guidance of $815 to $845 Million Representing >20% Growth Over Expected 2022 Revenue 2023 Recurring Revenues from Royalties Projected to Grow by >20% to $445 to $455 Million 2023 EBITDA Projected to Grow by >30% Year-Over-Year to $415 to $440 Million 2023 Non-GAAP Diluted EPS Guidance of $2. |
|
| January 10, 2023 |
Halozyme Confidential and Proprietary 1 41st Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 10, 2023 Halozyme Confidential and Proprietary 2 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expecte |
|
| December 12, 2022 |
HALO / Halozyme Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Halozyme Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 40637H109 Date of Event Which Requires Filing of this Statement: November 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| November 8, 2022 |
Exhibit 10.3 HALOZYME THERAPEUTICS, INC. SEVERANCE POLICY Under the Severance Policy of Halozyme Therapeutics, Inc. (the ?Company?), the particular amount of cash severance for an employee terminated by the Company without ?Cause? (as defined below) will generally be dictated by the employee?s position in the organization as well their completed years of service with the Company. The Severance Pol |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZY |
|
| November 8, 2022 |
Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan Exhibit 10.4 HALOZYME THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1 1. Establishment, Purpose and Term of Plan 4 1.1 Establishment 4 1.2 Purpose 4 1.3 Term of Plan 4 2. Definitions and Construction 4 2.1 Definitions 4 2.2 Construction 7 3. Administration 7 3.1 Administration by the Committee 7 3.2 Authority of Officers 7 3.3 Power to Vary Terms with Respect to Non-U.S. Employees 7 3.4 Pow |
|
| November 8, 2022 |
Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS Third Quarter Revenue Increased 80% YOY to $209 million, with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.741 Record Third Quarter Royalty Revenue Increased 70% YOY to $99.6 million Reiterating 2022 Revenue Guidance of $655 Million to $685 Million, Representing 48%-55% Growth |
|
| August 19, 2022 |
Amendment No. 1 to the Credit Agreement Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO THE CREDIT AGREEMENT AMENDMENT NO. 1 to the CREDIT AGREEMENT, dated as of August 18, 2022 (this ?Amendment?), among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the ?Borrower?), the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party hereto, BANK OF AMERICA, N.A., as administrative agent (in such capacit |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 18, 2022 |
Form of Capped Call Confirmation Exhibit 10.1 []1 To: Halozyme Therapeutics, Inc. 11388 Sorrento Valley Road San Diego, CA 92121 From: [] Re: [Base]2[Additional]3 Capped Call Transaction Ref. No: []4 Date: [] Dear Ladies and Gentlemen: The purpose of this communication (this ?Confirmation?) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the ?Transaction |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 18, 2022 |
Exhibit 4.1 CONFORMED VERSION HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of August 18, 2022 1.00% Convertible Senior Notes due 2028 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 12 Section 1.03. Rules of Construction 13 Article 2. The Notes 13 Sect |
|
| August 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 16, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 SAN DIEGO, CA (August 15, 2022) ? Halozyme Therapeutics, Inc. (NASDAQ: HALO) (?Halozyme? or the ?Company?), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $625.0 million aggregate principal |
|
| August 15, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028 The Company plans to purchase up to $200 million worth of shares concurrently with, or shortly after, the pricing of the offering SAN DIEGO, CA (August 15, 2022) ? Halozyme Therapeutics, Inc. (NASDAQ: HALO) (?Halozyme? or the ?Company?), a leader in conver |
|
| August 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 9, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No.1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME TH |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| August 9, 2022 |
NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99. |
|
| August 9, 2022 |
Exhibit 99.1 HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022 Second Quarter Revenue Increased 12% YOY to $152.4 million, with GAAP Diluted Earnings per Share of $0.16 and Non-GAAP Diluted Earnings per Share of $0.53 Record Second Quar |
|
| May 24, 2022 |
Exhibit 10.2 Execution Version SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of May 24, 2022 (this ?Agreement?), is by and among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the ?Borrower?), and certain of its Subsidiaries from time to time party hereto (collectively, together with the Borrower, the ?Grantors?) and BANK OF AMERICA, N.A., as administrative agent (in such capacity, th |
|
| May 24, 2022 |
Exhibit 10.1 Execution Version Published CUSIP Number: 40637KAC6 Published Revolver CUSIP Numbers: 40637KAD4 Published Term A CUSIP Number: 40637KAE2 CREDIT AGREEMENT Dated as of May 24, 2022 among HALOZYME THERAPEUTICS, INC., as the Borrower, BANK OF AMERICA, N.A., as Administrative Agent, a Swing Line Lender and an L/C Issuer, and The Other Lenders and L/C Issuers Party Hereto BofA SECURITIES, I |
|
| May 24, 2022 |
Halozyme Completes Antares Pharma Acquisition Exhibit 99.1 Halozyme Completes Antares Pharma Acquisition SAN DIEGO, May 24, 2022 ? Halozyme Therapeutics, Inc. (NASDAQ: HALO) (?Halozyme?) today announced the successful completion of its acquisition of Antares Pharma, Inc. (?Antares?). The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May 23, |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons ? Offerors) Common Stock, Par Value $0.01 Per Share (Title of Class o |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 24, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of in |
|
| May 12, 2022 |
Hart-Scott-Rodino Waiting Period Expires for Halozyme’s Acquisition of Antares Pharma Exhibit (a)(5)(K) Hart-Scott-Rodino Waiting Period Expires for Halozyme?s Acquisition of Antares Pharma SAN DIEGO, May 12, 2022 ? Halozyme Therapeutics, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons ? Offerors) Common Stock, Par Value $0.01 Per Share (Title of Class o |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME T |
|
| May 10, 2022 |
Exhibit 99.1 HALOZYME REPORTS FIRST QUARTER 2022 RESULTS First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47 Record Quarterly Royalties in the First Quarter of $69.6 million, Representing 89% Growth over First Quarter 2021 Reiterate 2022 Revenue Guidance of $530 Million to $560 Mill |
|
| May 10, 2022 |
AGREEMENT FOR ASSIGNMENT AND ASSUMPTION OF LEASE This Agreement for Assignment and Assumption of Lease (this "Assignment Agreement"), is made as of March 8, 2022 (the "Effective Date"), by and between SEISMIC SOFTWARE, INC. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of in |
|
| May 6, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons ? Offerors) Common Stock, Par Value $0.01 Per Share (Title of Class o |
|
| May 2, 2022 |
BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 Exhibit (b)(2) STRICTLY CONFIDENTIAL Execution Version BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 WELLS FARGO BANK, NATIONAL ASSOCIATION WELLS FARGO SECURITIES, LLC 550 South Tyron Street Charlotte, NC 28202 CONFIDENTIAL April 28, 2022 PROJECT ATLAS $375.0 million Term Loan Facility Amended and Restated Commitment Letter Halozyme Therapeutics, Inc. 11388 S |
|
| May 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit (d)(2) CONFIDENTIALITY AGREEMENT This agreement (this ?Agreement?), dated February 18, 2022 (the ?Effective Date?), shall serve to set forth the terms and conditions between Antares Pharma, Inc. |
|
| April 26, 2022 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| April 26, 2022 |
HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA Exhibit (a)(5)(J) HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA SAN DIEGO, April 26, 2022 ? Halozyme Therapeutics, Inc. |
|
| April 26, 2022 |
BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 Exhibit (b)(1) BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 CONFIDENTIAL April 12, 2022 PROJECT ATLAS $75.0 million Revolving Credit Facility $375.0 million Term Loan Facility Commitment Letter Halozyme Therapeutics, Inc. 11388 Sorrento Valley Road San Diego, CA 92121 Email: [email protected] Phone: (858) 794-8889 Ladies and Gentlemen: Halozyme Therapeutics |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons ? Offerors) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 0366 |
|
| April 26, 2022 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
EX-FILING FEES 11 d347764dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) ANTARES PHARMA, INC. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. a wholly owned subsidiary of HALOZYME THERAPEUTICS, INC. (Names of Filing Persons (Offerors)) Table 1-Transaction Valuation Transaction Valuation* Fee rate Amount of Filing Fee** Fees to Be |
|
| April 26, 2022 |
[Remainder of this page intentionally left blank.] Exhibit (d)(3) STRICTLY PRIVATE AND CONFIDENTIAL March 17, 2022 Robert F. Apple President and Chief Executive Officer Antares Pharma, Inc. 100 Princeton South, Suite 300 Ewing, New Jersey 08628 Re: Exclusivity Agreement Dear Bob: Reference is made to our discussions regarding a possible negotiated acquisition (the ?Proposed Transaction?) of all of the issued and outstanding shares of common stock |
|
| April 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| April 14, 2022 |
Exhibit (a)(5)(G) REFINITIV STREETEVENTS EDITED TRANSCRIPT HALO.OQ - Halozyme Therapeutics Inc to Acquire Antares Pharma Inc to Create a Specialty Product and Drug Delivery Leader Call EVENT DATE/TIME: APRIL 13, 2022 / 12:00PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ?2022 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing |
|
| April 14, 2022 |
SC TO-C 1 d339898dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ANTARES PHARMA, INC. (Name of Subject Company) ATLAS MERGER SUB, INC. a wholly owned subsidiary of HALOZYME THERAPEUTICS, INC. (Names of Filing Persons — Offerors) Common Stock, Par V |
|
| April 13, 2022 |
Exhibit 99.1 Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix w |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 12, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| April 13, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among HALOZYME THERAPEUTICS, INC., ATLAS MERGER SUB, INC. and ANTARES PHARMA, INC. Dated as of April 12, 2022 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 4 ARTICLE II MERGER TRANSACTION 5 Section 2.1 Merger of Purchaser into the Company 5 Section 2.2 Effect of the Merger 5 Section 2.3 Closing; Effective T |
|
| April 13, 2022 |
Halozyme to Acquire Antares Pharma April 13, 2022 Investor Conference Call Exhibit 99. |
|
| April 13, 2022 |
Exhibit (a)(5)(A) To: Antares Employees From: Helen Torley Date: April 13, 2022 Subject: Welcome to the Halozyme Team Dear Antares Team, What an exciting day for both of our companies. |
|
| April 13, 2022 |
Creating a Specialty Product and Drug Delivery Leader with Antares Exhibit (a)(5)(D) Creating a Specialty Product and Drug Delivery Leader with Antares April 13, 2022 Dear [INSERT]: Today, we announced that Halozyme is acquiring Antares Pharma, Inc. |
|
| April 13, 2022 |
Exhibit (a)(5)(C) Employee FAQ 1. What was announced? ? We recently announced that Halozyme is acquiring Antares to create an industry-leading, drug delivery and specialty product company. ? Both companies possess highly complementary science, products and capabilities, and, together, we will be able to offer even more opportunities for our team and benefits for patients. 2. Who is Antares? ? Anta |
|
| April 13, 2022 |
EX-99.(A)(5)(B) 3 d337959dex99a5b.htm EX-99.(A)(5)(B) Exhibit (a)(5)(B) To: Halozyme Employees From: Helen Torley Date: April 13, 2022 Subject: Creating a Specialty Product and Drug Delivery Leader with Antares Dear Colleagues, I am writing to you all today to share some important news. Moments ago, we announced that Halozyme is acquiring Antares Pharma for $5.60 per share in cash. I am excited ab |
|
| April 13, 2022 |
SC TO-C 1 d337959dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ANTARES PHARMA, INC. (Name of Subject Company) ATLAS MERGER SUB, INC. a wholly owned subsidiary of HALOZYME THERAPEUTICS, INC. (Names of Filing Persons — Offerors) Common Stock, Par V |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 12, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| April 13, 2022 |
EX-99.(A)(5)(E) 6 d337959dex99a5e.htm EX-99.(A)(5)(E) Exhibit (a)(5)(E) Halozyme to Acquire Antares to Create a Specialty Product and Drug Delivery Leader Expected to be Immediately Accretive to Revenue and Earnings Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Three Commercial Products Targeting Ke |
|
| April 13, 2022 |
Exhibit (a)(5)(F) Twitter Post LinkedIn Post Forward Looking Statements This communication contains ?forward-looking statements?. |
|
| March 25, 2022 |
DEF 14A 1 halodefproxy2022.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rul |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 15, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| February 22, 2022 |
Halozyme Therapeutics, Inc Directors Deferred Equity Compensation Plan HALOZYME THERAPEUTICS, INC. DIRECTORS DEFERRED EQUITY COMPENSATION PLAN 1. PURPOSE OF PLAN The purpose of this Plan is to afford members of the Board who are not officers or employees of the Corporation or one of its Subsidiaries the opportunity to defer the payment of certain compensation and equity awards paid or granted, as the case may be, for their service on the Board in the form of Stock Un |
|
| February 22, 2022 |
EXHIBIT 21.1 SUBSIDIARIES OF HALOZYME THERAPEUTICS, INC. Name of Subsidiary State or Jurisdiction of Incorporation or Organization Percent Owned Halozyme, Inc. California 100% Halozyme Switzerland GmbH, a wholly owned subsidiary of Halozyme Switzerland Holdings GmbH Switzerland 100% Halozyme Switzerland Holdings GmbH, a wholly owned subsidiary of Halozyme, Inc. Switzerland 100% |
|
| February 22, 2022 |
Halozyme Therapeutics, Inc. Non Qualified Deferred Compensation Plan Adoption Agreement EX-10.38 3 ex1038-nonqualifieddeferre.htm EX-10.38 NOTE: Execution of this Adoption Agreement creates a legal liability of the Employer with significant tax consequences to the Employer and Participants. Principal Life Insurance Company disclaims all liability for the legal and tax consequences which result from the elections made by the Employer in this Adoption Agreement. Nothing set forth in th |
|
| February 22, 2022 |
Exhibit 99.1 HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS ? Reports Fourth Quarter Revenue of $102.0 million with GAAP Diluted Earnings per Share of $0.46 and Non-GAAP Diluted Earnings per Share of $0.42 ? ? Reports Full Year 2021 Revenue of $443.3 million with GAAP Diluted Earnings per Share of $2.74 and Non-GAAP Diluted Earnings per Share of $2.00 ? ? 2022 Revenue Guidance of $530 |
|
| February 22, 2022 |
DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Halozyme Therapeutics, Inc. |
|
| February 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC |
|
| February 10, 2022 |
HALO / Halozyme Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01039-halozymetherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Halozyme Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 40637H109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box |
|
| February 4, 2022 |
SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2. |
|
| February 3, 2022 |
Halozyme Appoints New Chief Financial Officer EX-99.1 2 ex991-halozymenewcfoxanno.htm EX-99.1 Halozyme Appoints New Chief Financial Officer SAN DIEGO, February 2, 2022 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse will succeed Elaine Sun, who is stepping down to pursue another opportunity |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| January 28, 2022 |
HALO / Halozyme Therapeutics, Inc. / BlackRock Inc. Passive Investment us40637h1095012822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) HALOZYME THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 40637H109 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 10, 2022 |
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK ? 2022 Revenue Guidance of $530 to $560 Million Representing 23-26% Growth over Expected 2021 Revenue ? ? 2022 Recurring Revenue from Royalties Projected to Grow by Approximately 50% over Record Royalties in 2021 to Approximately $300 Million ? ? 2022 GAAP Operating Income Guidance of $350 to $380 Million Representing 32-36% Growth over Expected 2021 GAAP Operating Income ? ? 2022 GAAP Diluted EPS Guidance of $1. |
|
| January 10, 2022 |
EX-99.2 3 ex992halozymecorporatep.htm EX-99.2 Halozyme Confidential and Proprietary 40th Annual J.P. Morgan Healthcare Conference Dr. Helen Torley, President and CEO January 10, 2022 Halozyme Confidential and Proprietary 2 Forward-Looking Statements Note: This presentation contains product names, trademarks and registered trademarks are property of their respective owners In addition to historical |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| December 29, 2021 |
Execution Version Published CUSIP Number: 40637KAA0 CREDIT AGREEMENT Dated as of December 23, 2021 among HALOZYME THERAPEUTICS, INC. |
|
| December 29, 2021 |
EX-10.2 3 ex102halo-securityagreement.htm EX-10.2 Execution Version SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of December 23, 2021 (this “Agreement”), is by and among HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), and certain of its Subsidiaries which are, from time to time, “Domestic Loan Parties” (as defined in the Credit Agreement) (collectively, together with |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| December 13, 2021 |
HALOZYME APPOINTS NEW GENERAL COUNSEL EX-99.1 2 ex991halozymegcxannouncem.htm EX-99.1 HALOZYME APPOINTS NEW GENERAL COUNSEL SAN DIEGO, December 13, 2021 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective January 3, 2022. Mr. Snyder will succeed Masaru Matsuda, who is stepping down to pursue |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 8, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| December 10, 2021 |
BYLAWS OF HALOZYME THERAPEUTICS, INC. ARTICLE I STOCKHOLDERS 1.1 Place of Meetings. All meetings of stockholders shall be held at such place (if any) within or without the State of Delaware as may be designated from time to time by the Board of Directors (the ?Board?). 1.2 Annual Meeting. The annual meeting of stockholders for the election of directors and for the transaction of such other busines |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction o |
|
| November 2, 2021 |
Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2021 RESULTS ? Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 ? ? Third Quarter Revenue of $115.8 million with GAAP Diluted Earnings per Share of $1.48 and Non-GAAP Diluted Earnings per Share of $0.55 ? ? Increasing Lower End of Revenue and Operating Income 2021 Guidance Ranges to Reflect |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZY |
|
| November 2, 2021 |
Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2021 RESULTS ? Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 ? ? Third Quarter Revenue of $115.8 million with GAAP Diluted Earnings per Share of $1.48 and Non-GAAP Diluted Earnings per Share of $0.55 ? ? Increasing Lower End of Revenue and Operating Income 2021 Guidance Ranges to Reflect |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction |
|
| August 9, 2021 |
Form of Restricted Stock Units Agreement For Irish Participants Halozyme Therapeutics, Inc. Restricted Stock Units Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1.Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2.Vesting. All of the Restricted Stock Units are nonvested and forfeitable as |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME TH |
|
| August 9, 2021 |
Exhibit 99.1 HALOZYME REPORTS SECOND QUARTER 2021 RESULTS ? Raising 2021 Revenue Guidance to $425-$445 Million from $375-$395 Million, GAAP Earnings Per Share Guidance to $1.55-$1.70 from $1.25-$1.40 and Non-GAAP Earnings per Share Guidance to $1.85-$2.00 from $1.55-$1.70? ? Second Quarter Revenue of $136.5 million with GAAP Diluted Earnings per Share of $0.62 and Non-GAAP Diluted Earnings per Sha |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME T |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of in |
|
| May 10, 2021 |
Exhibit 99.1 HALOZYME REPORTS FIRST QUARTER 2021 RESULTS ? First Quarter Revenue of $89.0 million, Up from $25.4 million in First Quarter of 2020 ? ? Record Quarterly Royalties in the First Quarter of $36.9 million Representing 119% Growth over First Quarter 2020 ? ? Reiterate 2021 Revenue Guidance of $375 Million to $395 Million Representing 40% to 48% Growth over 2020 Revenue ? ? Reiterate 2021 |
|
| May 7, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2021 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of inc |
|
| May 5, 2021 |
Form of Restricted Stock Award Agreement (2021 Stock Plan) Halozyme Therapeutics, Inc. Restricted Stock Award Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized words used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Termination of Employment or Service. (a) If your Service with the Company or successor ceases f |
|
| May 5, 2021 |
Form of Restricted Stock Units Agreement (2021 Stock Plan) Halozyme Therapeutics, Inc. Restricted Stock Units Agreement under the Halozyme Therapeutics, Inc. 2021 Stock Plan 1. Terminology. Unless otherwise provided in this Award Agreement, capitalized terms used herein are defined in the Glossary at the end of this Award Agreement, the Notice, or the Plan. 2. Vesting. All of the Restricted Stock Units are nonvested and forfeitable as of the Grant Date. S |
|
| May 5, 2021 |
HALOZYME THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1 1. Establishment, Purpose and Term of Plan 4 1.1 Establishment 4 1.2 Purpose 4 1.3 Term of Plan 4 2. Definitions and Construction 4 2.1 Definitions 4 2.2 Construction 7 3. Administration 7 3.1 Administration by the Committee 7 3.2 Authority of Officers 7 3.3 Power to Vary Terms with Respect to Non-U.S. Employees 7 3.4 Power to Establi |
|
| May 5, 2021 |
As filed with the Securities and Exchange Commission on May 5, 2021 Registration No. |
